Vectomat Insights has published a comprehensive market study for the global CAR-T cell therapy market, forecasting growth from USD 4,372.8 million in 2025 to USD 23,915.3 million by 2035 (18.52% CAGR).

Key highlights include:
- Products & Antigens: Autologous CAR-T therapies hold 68.0% of 2025 revenue, while off-the-shelf allogeneic CAR-T products represent the fastest-growing segment at a 28.63% CAGR, overtaking autologous revenue before 2035. CD19-targeted therapies lead current antigen share at 57.0%, whereas BCMA-targeted treatments compound fastest at 26.06% annually. Non-Hodgkin lymphoma accounts for 35.5% of application revenue, and hospitals and cancer centers represent 65.3% of end-user spend.
- Regional Dynamics: North America leads global demand with a 45.0% market share (USD 1,967.8 million), supported by the U.S. market (USD 1,574.2 million) and the FDA's removal of REMS programs for approved autologous CAR-T therapies. Europe follows at 27.0%, while Asia-Pacific (19.0%) expands fastest, driven by domestic approvals in South Korea and China's first solid-tumor CAR-T clearance.
- Industry Milestones: Major developments include Gilead Sciences' USD 7.8 billion acquisition of Arcellx, significant in-vivo CAR-T investments from AstraZeneca and AbbVie, and CARsgen Therapeutics' NMPA approval for satri-cel in advanced gastric cancer.

Access a free sample or the full 300-page report covering 35 countries and 15 company profiles at: https://www.vectomatinsights.com/request-sample?report=car-t-cell-therapy-market
Purchase the full report at: https://www.vectomatinsights.com/checkout?report=car-t-cell-therapy-market

About Vectomat Insights
Vectomat Insights is an independent market research firm delivering audited, analyst-validated 10-year forecasts and strategic intelligence across healthcare and life sciences.